James Updike

Jim Updike was appointed Chief Business Office of Kira Biotech in August 2021. At Kira Biotech, Jim will be responsible for leading the execution of strategic business and corporate development activities as Kira Biotech seeks to expand its immunology-focused portfolio and build out its capabilities in the United States. Jim has led high-impact teams in the execution of critical projects.

Jim is an industry veteran with decades of experience in leading business development activities in global pharmaceutical companies, development-stage and specialty pharmaceuticals companies. He has a broad industry network and a deep skill set in the areas of business development, corporate strategy and operations.

Prior to joining Kira Biotech, Jim founded a life sciences transaction advisory firm, Harbor Point Advisors, where he advised firms in area of business development strategy and implementation. Prior to Harbor Point, he held the position of Senior Vice President, Business Development at Assertio Therapeutics (successor by merger to Zyla Life Sciences). During his tenure, he completed a number of transactions to grow the U.S. business of Zyla. Prior to Assertio, Jim held a number of positions in leading companies including Teva and Wyeth.

Jim holds a B.S. in Biology from the University of Richmond and an MBA from the American University – Kogod School of Business, where he was a Graduate Fellow during his studies.